Personalis (NASDAQ:PSNL) CFO Aaron Tachibana Sells 40,000 Shares

Personalis, Inc. (NASDAQ:PSNL) CFO Aaron Tachibana sold 40,000 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $12.01, for a total value of $480,400.00. Following the completion of the sale, the chief financial officer directly owned 198,833 shares in the company, valued at $2,387,984.33. This represents a 16.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Aaron Tachibana also recently made the following trade(s):

• On Friday, May 29th, Aaron Tachibana sold 38,799 shares of Personalis stock. The stock was sold at an average price of $11.58, for a total value of $449,292.42.

Personalis Price Performance

Shares of NASDAQ PSNL opened at $10.75 on Friday. Personalis, Inc. has a 1-year low of $3.84 and a 1-year high of $12.53. The business’s fifty day moving average price is $7.23 and its two-hundred day moving average price is $8.21. The firm has a market capitalization of $1.13 billion, a PE ratio of -10.54 and a beta of 2.28.

Personalis (NASDAQ:PSNL) last issued its earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.06). Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%.The company had revenue of $15.47 million during the quarter, compared to analyst estimates of $14.49 million. Equities research analysts expect that Personalis, Inc. will post -1.06 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

PSNL has been the topic of a number of research analyst reports. BTIG Research lowered their price target on Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Monday, May 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a report on Tuesday, April 21st. Needham & Company LLC raised their price target on Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a report on Friday, February 27th. Wall Street Zen raised Personalis from a “sell” rating to a “hold” rating in a report on Saturday, May 30th. Finally, Morgan Stanley lowered their price target on Personalis from $10.00 to $9.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $11.00.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd grew its holdings in Personalis by 76.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after acquiring an additional 1,479 shares during the period. Deutsche Bank AG grew its holdings in Personalis by 4.5% during the fourth quarter. Deutsche Bank AG now owns 38,827 shares of the company’s stock worth $309,000 after acquiring an additional 1,655 shares during the period. Royal Bank of Canada boosted its stake in shares of Personalis by 3.2% during the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock worth $275,000 after acquiring an additional 2,395 shares in the last quarter. Howland Capital Management LLC boosted its stake in shares of Personalis by 0.9% during the 2nd quarter. Howland Capital Management LLC now owns 285,308 shares of the company’s stock worth $1,872,000 after acquiring an additional 2,500 shares in the last quarter. Finally, Intech Investment Management LLC increased its stake in Personalis by 23.4% in the 4th quarter. Intech Investment Management LLC now owns 20,342 shares of the company’s stock worth $162,000 after purchasing an additional 3,851 shares in the last quarter. 61.91% of the stock is owned by institutional investors and hedge funds.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.